WD-1905

WD-1905 is a small molecule drug candidate developed by WD Pharmaceutical (also known as Wanda Pharmaceutical) for the treatment of morning akinesia in patients with Parkinson's disease. Morning akinesia is a common 'OFF' period complication where patients experience severe rigidity or loss of motor function upon waking, resulting from the overnight depletion of dopaminergic medications. WD-1905 utilizes proprietary drug delivery technology, likely an oral controlled-release or micro-pump mechanism, to provide sustained dopaminergic stimulation and ensure therapeutic levels are present in the early morning hours. The candidate is currently in Phase 2 clinical development and aims to improve the quality of life for patients experiencing early morning motor fluctuations.